Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Accelerating the Science of SCD Therapies—Is a Cure Possible?
source: JAMA
year: 2019
authors: Edward J. Benz Jr, Traci Heath Mondoro, Gary H. Gibbons
summary/abstract:Nearly 7 decades have passed since seminal studies of hemoglobin led to the characterization of sickle cell anemia as the first defined molecular disease. These foundational insights into sickle cell disease (SCD) initiated an exciting era of medicine that has substantially expanded the understanding of the molecular basis of thousands of disorders over the ensuing years. The field of molecular medicine is now at a pivotal moment in its history, a time when scientific capabilities to read, edit, and reprogram the human genetic code for therapeutic approaches are within reach. The rapid pace of innovation in emerging technologies of gene editing and translational research suggest that it is time to accelerate curative therapies for the first defined molecular disease.
organization: Dana-Farber Cancer Institute, USA; National Institutes of Health, USADOI: 10.1001/jama.2019.11419
read more
+myBinderRelated Content
-
A multiple drug approach to preventing sickle cell crisisSickle cell disease is characterized by ...
-
Gabapentin for Pain in Sickle Cell Disease: Results of a Randomized Phase ll Clinical TrialBackground: Pain in sickle cell disease...
-
World’s Largest Sickle Cell Disease Stem Cell Library UnderwayScientists in Boston are creating a stem...
-
Nitric Oxide, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators as Candidate Treatments for Sic...Despite being described in the medical l...
-
Investigational Oral Inhibitor IMR-687 Shows Promising Results in Ongoing Phase 2 Clinical TrialImara’s investigational oral inhibitor...
-
Crizanlizumab designated FDA breakthrough therapy for potential in vaso-occlusive crisis preventionCrizanlizumab (SEG101), Novartis‘ inve...
-
BCL11A-based gene therapy for sickle cell disease passes key preclinical testA precision-engineered gene therapy viru...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.